A clinical-stage biotechnology company in immunotherapy

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

03/01/2023

OSE Immunotherapeutics Announces Upcoming Investor Meetings in Q1 2023

Download

To receive OSE Immunotherapeutics’ latest news

[sibwp_form id=3]